GeneXpert—A Game-Changer for Tuberculosis Control?

1. World Health Organization 2010 Global tuberculosis control Geneva World Health Organization

2. BoehmeCCNabetaPHillemannDNicolMPShenaiS 2010 Rapid molecular detection of tuberculosis and rifampin resistance. N Engl J Med 363 11 1005 1015

3. BoehmeCCNicolMPNabetaPMichaelJSGotuzzoE 2011 Feasibility, diagnostic accuracy, and effectiveness of decentralised use of the Xpert MTB/RIF test for diagnosis of tuberculosis and multidrug resistance: a multicentre implementation study. Lancet 377 9776 1495 1505

4. NathansonENunnPUplekarMFloydKJaramilloE 2010 MDR tuberculosis–critical steps for prevention and control. N Engl J Med 363 11 1050 1058

5. CoxHKebedeYAllamuratovaSIsmailovGDavletmuratovaZ 2006 Tuberculosis recurrence and mortality after successful treatment: impact of drug resistance. PLoS Med 3 10 e384 doi:10.1371/journal.pmed.0030384

6. ChaudharyMGuptaSKhareSLalS 2010 Diagnosis of tuberculosis in an era of HIV pandemic: a review of current status and future prospects. Indian J Med Microbiol 28 4 281 289

7. WilsonML 2011 Recent advances in the laboratory detection of Mycobacterium tuberculosis complex and drug resistance. Clin Infect Dis 52 11 1350 1355

8. HelbDJonesMStoryEBoehmeCWallaceE 2010 Rapid detection of Mycobacterium tuberculosis and rifampin resistance by use of on-demand, near-patient technology. J Clin Microbiol 48 1 229 237

9. SmallPMPaiM 2010 Tuberculosis diagnosis–time for a game change. N Engl J Med 363 11 1070 1071

10. BlakemoreRStoryEHelbDKopJBanadaP 2010 Evaluation of the analytical performance of the Xpert MTB/RIF assay. J Clin Microbiol 48 7 2495 2501

11. LawnSDBrooksSVKranzerKNicolMWhitelawA 2011 Screening for HIV-associated tuberculosis and rifampicin resistance before antiretroviral therapy using the Xpert MTB/RIF assay: a prospective study. PLoS Med 8 7 e1001067 doi:10.1371/journal.pmed.1001067

12. ScottLEMcCarthyKGousNNdunaMVan RieA 2011 Comparison of Xpert MTB/RIF with other nucleic acid technologies for diagnosing pulmonary tuberculosis in a high HIV prevalence setting: a prospective study. PLoS Med 8 7 e1001061 doi:10.1371/journal.pmed.1001061

13. DowdyDW 2011 Is scale-up worth it? Challenges in economic analysis of diagnostic tests for tuberculosis. PLoS Med 8 7 e1001063 doi:10.1371/journal.pmed.1001063

14. Van RieAPage-ShippLScottLSanneIStevensW 2010 Xpert((R)) MTB/RIF for point-of-care diagnosis of TB in high-HIV burden, resource-limited countries: hype or hope? Expert Rev Mol Diagn 10 7 937 946

15. PaiMRamsayAO'BrienR 2008 Evidence-based tuberculosis diagnosis. PLoS Med 5 7 e156 doi:10.1371/journal.pmed.0050156

16. World Health Organization 2004 Respiratory care in primary care services – a survey in 9 countries. Practical Approach to Lung Health (PAL) Geneva World Health Organization

17. OteroLUgazRDieltiensGGonzalezEVerdonckK 2010 Duration of cough, TB suspects' characteristics and service factors determine the yield of smear microscopy. Trop Med Int Health 15 12 1475 1480

18. HinderakerSGRusenIDChiangCYYanLHeldalE 2011 The FIDELIS initiative: innovative strategies for increased case finding. Int J Tuberc Lung Dis 15 1 71 76

19. World Health Organization 2010 Multidrug and extensively drug-resistant TB (M/XDR-TB): 2010 global report on surveillance and response. Available: http://whqlibdoc.who.int/publications/2010/9789241599191_eng.pdf. Accessed 24 June 2011

20. KawaiVSotoGGilmanRHBautistaCTCaviedesL 2006 Tuberculosis mortality, drug resistance, and infectiousness in patients with and without HIV infection in Peru. Am J Trop Med Hyg 75 6 1027 1033

21. StallNRubinTMichaelJSMathaiDAbrahamOC 2011 Does solid culture for tuberculosis influence clinical decision making in India? Int J Tuberc Lung Dis 15 5 641 646

22. EdgintonMEMillerDLBurneyPEl SonyAILwillaFI 2010 Surveillance for MDR-TB: is there an obligation to ensure treatment for individuals identified with MDR-TB? Int J Tuberc Lung Dis 14 9 1094 1096

23. FurinJBayonaJBecerraMFarmerPGolubkovA 2011 Programmatic management of multidrug-resistant tuberculosis: models from three countries. Int J Tuberc Lung Dis 15 7). E-pub ahead of print 8 June 2011. doi:10.5588/ijtld.10.0591

24. MitnickCBayonaJPalaciosEShinSFurinJ 2003 Community-based therapy for multidrug-resistant tuberculosis in Lima, Peru. N Engl J Med 348 2 119 128

25. ReschSCSalomonJAMurrayMWeinsteinMC 2006 Cost-effectiveness of treating multidrug-resistant tuberculosis. PLoS Med 3 7 e241 doi:10.1371/journal.pmed.0030241

26. MartinezDHeudebertGSeasCHenostrozaGRodriguezM 2010 Clinical prediction rule for stratifying risk of pulmonary multidrug-resistant tuberculosis. PLoS ONE 5 8 e12082 doi:10.1371/journal.pone.0012082

27. World Health Organization STOP TB Department 2010 Roadmap for rolling out Xpert MTB/RIF for rapid diagnosis of TB and MDR-TB. Available: http://www.who.int/tb/laboratory/roadmap_xpert_mtb-rif.pdf. Accessed 24 June 2011

28. LonnrothKCastroKGChakayaJMChauhanLSFloydK 2010 Tuberculosis control and elimination 2010–50: cure, care, and social development. Lancet 375 9728 1814 1829

29. DyeCLonnrothKJaramilloEWilliamsBGRaviglioneM 2009 Trends in tuberculosis incidence and their determinants in 134 countries. Bull World Health Organ 87 9 683 691

30. OxladeOSchwartzmanKBehrMABenedettiAPaiM 2009 Global tuberculosis trends: a reflection of changes in tuberculosis control or in population health? Int J Tuberc Lung Dis 13 10 1238 1246

31. BenatarSRUpshurR 2010 Tuberculosis and poverty: what could (and should) be done? Int J Tuberc Lung Dis 14 10 1215 1221

32. RasanathanKSivasankara KurupAJaramilloELönnrothK 2011 The social determinants of health: key to global tuberculosis control. Int J Tuberc Lung Dis 15 Supplement 2 S30 S36

33. CreswellJJaramilloELonnrothKWeilDRaviglioneM 2011 Tuberculosis and poverty: what is being done. Int J Tuberc Lung Dis 15 4 431 432